Nektar Therapeutics (NASDAQ: NKTR), a United States-based biopharmaceutical company, has named Brian Kotzin, MD as its interim chief medical officer, head of Development effective immediately, it was reported on Tuesday.
Dr Kotzin was the senior vice president, Clinical Development and head of Immunology at Nektar. He has held the position of vice president, Global Clinical Development and head of the Inflammation Therapeutic area at Amgen, head of Clinical Immunology in the Department of Medicine and director of the Autoimmunity Center of Excellence at the University of Colorado Health Sciences Center in Denver, professor in the Departments of Medicine, Paediatrics, and Immunology at the National Jewish Medical and Research Center in Denver and chief of the Rheumatology Section at the Veterans Administration Medical Center in Denver.
Dr. Kotzin holds a BS in mathematics from the University of Southern California and an MD from Stanford University School of Medicine and is a postdoctoral fellow in the Division of Immunology and Rheumatology at Stanford University School of Medicine and board certified in rheumatology and internal medicine.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins